Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1152515.RABNdJLW-J3bZSliNrFMWNShnfevnBxsn8_cLLCUbb8Rs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1152515.RABNdJLW-J3bZSliNrFMWNShnfevnBxsn8_cLLCUbb8Rs130_assertion type Assertion NP1152515.RABNdJLW-J3bZSliNrFMWNShnfevnBxsn8_cLLCUbb8Rs130_head.
- NP1152515.RABNdJLW-J3bZSliNrFMWNShnfevnBxsn8_cLLCUbb8Rs130_assertion description "[We found that SNPs rs3212986 (odds ratio [OR] = 1.35 (1.08-1.68), P = .008), rs13181 (OR = 1.18 (1.06-1.31), P = .002), and rs25487 (OR = 1.12 (1.03-1.22), P = .007) in DNA repair genes ERCC1, ERCC2 (XPD), and XRCC1 may increase the risk of glioma, while polymorphisms rs1136410 (OR = 0.78 (0.68-0.89), P = .0004) and rs12917 (OR = 0.84 (0.73-0.96), P = .01) in PARP1(ADPRT) and MGMT are associated with decreased susceptibility to glioma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1152515.RABNdJLW-J3bZSliNrFMWNShnfevnBxsn8_cLLCUbb8Rs130_provenance.
- NP1152515.RABNdJLW-J3bZSliNrFMWNShnfevnBxsn8_cLLCUbb8Rs130_assertion evidence source_evidence_literature NP1152515.RABNdJLW-J3bZSliNrFMWNShnfevnBxsn8_cLLCUbb8Rs130_provenance.
- NP1152515.RABNdJLW-J3bZSliNrFMWNShnfevnBxsn8_cLLCUbb8Rs130_assertion SIO_000772 24500421 NP1152515.RABNdJLW-J3bZSliNrFMWNShnfevnBxsn8_cLLCUbb8Rs130_provenance.
- NP1152515.RABNdJLW-J3bZSliNrFMWNShnfevnBxsn8_cLLCUbb8Rs130_assertion wasDerivedFrom befree-2016 NP1152515.RABNdJLW-J3bZSliNrFMWNShnfevnBxsn8_cLLCUbb8Rs130_provenance.
- NP1152515.RABNdJLW-J3bZSliNrFMWNShnfevnBxsn8_cLLCUbb8Rs130_assertion wasGeneratedBy ECO_0000203 NP1152515.RABNdJLW-J3bZSliNrFMWNShnfevnBxsn8_cLLCUbb8Rs130_provenance.